Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 11 (Search time: 0.002 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2010
Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatment
Kim, D.
;
Kim, D.
;
Kim, S.
;
Goh, H.
;
Pane, F.
;
Hughes, T.
;
Radich, J.
;
Lin, P.
;
Saglio, G.
;
Branford, S.
;
Martinelli, G.
;
Soverini, S.
;
Hochhaus, A.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010
A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate
Branford, S.
;
Goh, H.
;
Izzo, B.
;
Beppu, L.
;
Ortmann, C.
;
Duniec, K.
;
Jin, Y.
;
Woodman, R.
;
Pane, F.
;
Kim, D.
;
Radich, J.
;
Hughes, T.
;
American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2013
Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia
Stein, A.
;
Martinelli, G.
;
Hughes, T.
;
Muller, M.
;
Beppu, L.
;
Gottardi, E.
;
Branford, S.
;
Soverini, S.
;
Woodman, R.
;
Hochhaus, A.
;
Kim, D.
;
Saglio, G.
;
Radich, J.
2008
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
le Coutre, P.
;
Ottmann, O.
;
Giles, F.
;
Kim, D.
;
Cortes, J.
;
Gattermann, N.
;
Apperley, J.
;
Larson, R.
;
Abruzzese, E.
;
O'Brien, S.
;
Kuliczkowski, K.
;
Hochhaus, A.
;
Mahon, F.
;
Saglio, G.
;
Gobbi, M.
;
Kwong, Y.
;
Baccarani, M.
;
Hughes, T.
;
Martinelli, G.
;
Radich, J.
;
et al.
2013
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy
Angelini, S.
;
Soverini, S.
;
Ravegnini, G.
;
Barnett, M.
;
Turrini, E.
;
Thornquist, M.
;
Pane, F.
;
Hughes, T.
;
White, D.
;
Radich, J.
;
Kim, D.
;
Saglio, G.
;
Cilloni, D.
;
Iacobucci, I.
;
Perini, G.
;
Woodman, R.
;
Cantelli-Forti, G.
;
Baccarani, M.
;
Hrelia, P.
;
Martinelli, G.
2009
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value
Hochhaus, A.
;
Muller, M.
;
Radich, J.
;
Branford, S.
;
Kantarjian, H.
;
Hanfstein, B.
;
Rousselot, P.
;
Kim, D.
;
Lipton, J.
;
Bleickhardt, E.
;
Lambert, A.
;
Hughes, T.
2009
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
Muller, M.
;
Cortes, J.
;
Kim, D.
;
Druker, B.
;
Erben, P.
;
Pasquini, R.
;
Branford, S.
;
Hughes, T.
;
Radich, J.
;
Ploughman, L.
;
Mukhopadhyay, J.
;
Hochhaus, A.
2011
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
Kantarjian, H.
;
Giles, F.
;
Bhalla, K.
;
Pinilla-Ibarz, J.
;
Larson, R.
;
Gattermann, N.
;
Ottmann, O.
;
Hochhaus, A.
;
Radich, J.
;
Saglio, G.
;
Hughes, T.
;
Martinelli, G.
;
Kim, D.
;
Shou, Y.
;
Gallagher, N.
;
Blakesley, R.
;
Baccarani, M.
;
Cortes, J.
;
le Coutre, P.
2010
Phase III, randomized, open-label study of daily Imatinib Mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
Cortes, A.
;
Baccarani, M.
;
Guilhot, F.
;
Druker, B.
;
Branford, S.
;
Kim, D.
;
Pane, F.
;
Pasquini, R.
;
Goldberg, S.
;
Kalaycio, M.
;
Moiraghi, B.
;
Rowe, J.
;
Tothova, E.
;
de Souza, C.
;
Rudoltz, M.
;
Yu, R.
;
Krahnke, T.
;
Kantarjian, H.
;
Radich, J.
;
Hughes, T.
2014
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study
Baccarani, M.
;
Druker, B.
;
Branford, S.
;
Kim, D.
;
Pane, F.
;
Mongay, L.
;
Mone, M.
;
Ortmann, C.
;
Kantarjian, H.
;
Radich, J.
;
Hughes, T.
;
Cortes, J.
;
Guilhot, F.
Discover
Author
7
Branford, S.
6
Hochhaus, A.
6
Martinelli, G.
6
Pane, F.
6
Saglio, G.
5
Baccarani, M.
4
Cortes, J.
4
Kantarjian, H.
4
Soverini, S.
4
Woodman, R.
.
next >
Subject
5
Adult
5
Aged
5
Humans
5
Middle Aged
5
Pyrimidines
4
Antineoplastic Agents
4
Benzamides
4
Female
4
Imatinib Mesylate
4
Male
.
next >
Date issued
1
2014
2
2013
1
2012
1
2011
3
2010
2
2009
1
2008